The prevalence of the G12D oncogenic mutation is much higher than others including G12C in pancreatic cancer and lung cancer (Prior et al., 2012; Ryan and Corcoran, 2018), but no inhibitor has been approved for the KRAS (G12D)-mutated cancer. The gene discussed is KRAS; the disease is cancer.